This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Hyperion Therapeutics Announces Third Quarter 2013 Financial Results

Stocks in this article: HPTX

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $15.5 million during the third quarter of 2013 which includes sales of its newly approved medication, RAVICTI ® (glycerol phenylbutyrate) Oral Liquid and the first full quarter of sales of BUPHENYL ® (sodium phenylbutyrate) Tablets and Powder following the company's acquisition of that product.

"We are pleased with the momentum of the Ravicti launch", said Donald J. Santel, president and chief executive officer of Hyperion Therapeutics. "With broad and extensive reimbursement coverage from private and public payers now secured and our robust patient support services, we are ensuring patients have affordable access to both RAVICTI and BUPHENYL, while maintaining a streamlined commercial infrastructure and efficient business."

Third Quarter 2013 Financial Results

Net income as measured under U.S. generally accepted accounting principles ("GAAP") was $0.1 million, or $0.01 earnings per diluted share for the three months ended September 30, 2013, compared with a net loss of $4.9 million, or $0.44 loss per diluted share for the same period of 2012. Adjusted net income was $3.2 million, or $0.15 earnings per diluted share, for the three months ended September 30, 2013, compared with an adjusted net loss of $4.6 million, or $0.41 loss per diluted share. A reconciliation of adjusted net income (loss) to GAAP net income (loss) is provided in the accompanying table below entitled "Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income (Loss)."


During the three months ended September 30, 2013, Hyperion generated net product revenue of $15.5 million from the sale of RAVICTI and BUPHENYL. Net product revenue for the period included $9.8 million in net sales from RAVICTI, a 58 percent increase from second quarter 2013 RAVICTI sales of $6.2 million, and $6.0 million in net sales from BUPHENYL. Net product revenue was partially offset by $0.3 million of co-payment assistance, a program to reduce financial burden for patients for both RAVICTI and BUPHENYL.

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,237.32 +168.45 0.99%
S&P 500 1,997.06 +24.32 1.23%
NASDAQ 4,609.1760 +61.3420 1.35%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs